Multiple myeloma (MM) is the most common plasma cell dyscrasia and accounts for approximately 10-13% of haematological malignancies. We studied tests of hemostasis including platelet count, Prothrombin time, Activated Partial Thromboplastin time, Thrombin time and plasma fibrinogen in 30 patients of multiple myeloma and 30 age matched controls. Prolongation of APTT was the most common screening test which was abnormal. One or more laboratory parameter of hemostasis was abnormal in all 30 (100%) patients. It has been reported that bleeding may occur as a late manifestation in these patients. Screening for these abnormalities and close follow up can help reduce morbidity and mortality and improve prognosis in these patients.
Impact Factor
2022: 6.012
This work is licensed under a